Figure 5

Migration, invasion & TGFβ response of cells and EVTs are blocked with Src inhibitors. (A) Morphology of the 344SQ cells in the indicated treatment conditions. (B) The migratory and invasive Transwell assays upon DMSO, Dasatinib (50 nM) or AZD0530 (3 μM) treatment. (C) Western Blot analysis of 344SQ and 531LN2 cells treated with Src inhibitors and TGFβ at the indicated concentrations for 3 days. (D) Sphere formation of 344SQ in 3D Matrigel cultures. Images were taken at day 10 and sphere size (E) and invasiveness scored (F). Dasatinib (50 nM) was added at day 4, AZD0530 (3 μM) at day 5 and TGFβ (5 ng/ml) at day 6. (G) EVTs culture in Matrigel for 8 days. Images were taken at day 8. Dasatinib (50 nM) was added at the time of seeding and TGFβ (5 ng/ml) at day 4. (H) Size of EVTs and invasiveness of EVTs on TGFβ and dasatinib treatments. (I) Western blot analysis of EVTs treated with Dasatinib and TGFβ at indicate concentrations.